Study on Sequential Immunization of Inactivated SARS-CoV-2 Vaccine and Recombinant SARS-CoV-2 Vaccine (Ad5 Vector)
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- COVID-19
- Type
- Interventional
- Phase
- Phase 4
- Design
- Allocation: RandomizedIntervention Model: Parallel AssignmentIntervention Model Description: Subjects who have been primed with one dose or two doses of inactive SARS-CoV-2 vaccine will be recruited and randomized at a 1:1 ratio to receive a booster dose of inactive SARS-CoV-2 vaccine or recombinant SARS-CoV-2 Ad5 vectored vaccineMasking: Triple (Participant, Investigator, Outcomes Assessor)Masking Description: Unblinded staff will responsible for the vaccine administration and management, and other investigators will be kept blinded.Primary Purpose: Prevention
Participation Requirements
- Age
- Between 18 years and 59 years
- Gender
- Both males and females
Description
Not Provided
Not Provided
Tracking Information
- NCT #
- NCT04892459
- Collaborators
- CanSino Biologics Inc.
- Investigators
- Principal Investigator: Jing-Xin Li, PhD Jiangsu Provincial Center for Diseases Control and Prevention